CTLA4 and hypophysitis: Interestingly, Tahir et al. evaluated another approach to identify a novel biomarker using the combined RNA and protein expressions of autoantibodies in patients with solid tumors who received anti-PD1 with or without anti-CTLA-4 and developed hypophysitis irAEs.